NCT00790114已完成1 期
A Phase I Open-Labeled, Fixed Sequence Study to Determine the Effect of Multiple Doses of AZD7325 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 24
- 主要终点
- To determine the effects of repeated doses of AZD7325 on the pharmacokinetic profile of a CYP3A4 substrate (midazolam and its 1' hydroxy metabolite) and a CYP1A2 substrate (caffeine and its paraxanthine [3-desmethyl] metabolite).
研究概览
简要总结
To determine the effects of repeated doses of AZD7325 on the pharmacokinetic profile of a CYP3A4 substrate (midazolam and its 1' hydroxy metabolite) and a CYP1A2 substrate (caffeine and its paraxanthine [3-desmethyl] metabolite).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator and/or sponsor.
- •Enrollment in another concurrent investigational study or intake of an investigational drug within 3 months or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit
研究组 & 干预措施
1
Experimental
干预措施: Caffeine (Drug)
1
Experimental
干预措施: Midazolam (Drug)
1
Experimental
干预措施: AZD7325 (Drug)
结局指标
主要结局
To determine the effects of repeated doses of AZD7325 on the pharmacokinetic profile of a CYP3A4 substrate (midazolam and its 1' hydroxy metabolite) and a CYP1A2 substrate (caffeine and its paraxanthine [3-desmethyl] metabolite).
时间窗: Blood samples will be taken during the study.
次要结局
- To evaluate the safety and tolerability of repeated doses of AZD7325 in combination with midazolam and caffeine.(Blood samples will be taken during the study.)
- Evaluation of the pharmacodynamic effects of AZD7325(Test batteries will be performed at specified times both before and following study drug administration.)
- To evaluate the pharmacokinetics of AZD7325(Blood samples will be taken on Days 1, 11 and 12.)
研究者
相似试验
暂停
1 期
Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female SubjectsPharmacokineticsNCT00901290AstraZeneca56
已完成
1 期
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and DigoxinHealthy ParticipantsNCT05395117AstraZeneca32
已完成
1 期
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.Healthy ParticipantsNCT06494644AstraZeneca17
已完成
1 期
A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood LevelsHealthyNCT01069822AstraZeneca46
已完成
1 期
A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy SubjectsCardiovascular DiseaseNCT04492709AstraZeneca14